Cardiovascular Risk Associated With NSAIDs and COX-2 Inhibitors
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study | Annals of the Rheumatic Diseases
Diclofenac use and cardiovascular risks: series of nationwide cohort studies | The BMJ
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
Study of gastrointestinal toxicity of selective COX-2 inhibitors in comparison with conventional NSAIDs - | Semantic Scholar
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction - ScienceDirect
Diclofenac vs. ibuprofen: Differences, similarities, and which is better for you
PDF) Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients – topic of research paper in Clinical medicine. Download scholarly article PDF and read for free on
Cardiovascular Risks of Diclofenac Versus Other Older COX-2 Inhibitors (Meloxicam and Etodolac) and Newer COX-2 Inhibitors (Celecoxib and Etoricoxib): A Series of Nationwide Emulated Trials | SpringerLink
Cardiorenal effects of celecoxib as compared with the nonsteroidal anti-inflammatory drugs diclofenac and ibuprofen - ScienceDirect
Gastrointestinal safety of celecoxib versus naproxen in patients with cardiothrombotic diseases and arthritis after upper gastrointestinal bleeding (CONCERN): an industry-independent, double-blind, double-dummy, randomised trial - The Lancet
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison - ScienceDirect
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial | Semantic Scholar
Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction | Journal of the American College of Cardiology
Emerging Evidence in NSAID Pharmacology: Important Considerations for Product Selection
Lessons from 20 years with COX‐2 inhibitors: Importance of dose–response considerations and fair play in comparative trials - Stiller - 2022 - Journal of Internal Medicine - Wiley Online Library
Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial - The Lancet
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
Celecoxib versus diclofenac for the treatment of ankylosing spondylitis: 12-week randomized study in Norwegian patients - Chris Walker, Margaret N Essex, Chunming Li, Peter W Park, 2016
Celecoxib versus Diclofenac and Omeprazole in Reducing the Risk of Recurrent Ulcer Bleeding in Patients with Arthritis | NEJM
Selective COX-2 inhibitors: Are they safer NSAIDs?
Naproxen vs. Ibuprofen: Which Is the Better NSAID Pain Reliever? - GoodRx
Celecoxib Versus Naproxen and Diclofenac in Osteoarthritis Patients: SUCCESS-I Study - ScienceDirect